Washington, DC 20006-5349
HELPLINE
A new approach of anti-PD1 immunotherapy (atezolizumab) combined with bevacizumab (an agent that blocks the growth of new blood vessels therefore limiting the supply of…
Join us next Tuesday, June 9 at 2:00 PM ET for a Meet the Mesothelioma Experts (MTME) interview with Dr. Zachary Horne on Facebook Live.…
A phase 2 immunotherapy clinical trial combining durvalumab, an immunotherapy drug, with standard treatment of Alimta (pemetrexed)/cisplatin has shown promising overall survival results. The study enrolled 55 patients and…
In 2016, the Mesothelioma Applied Research Foundation funded a grant to Antonio Giordano, MD, PhD, director and founder of the Sbarro Health Research Organization at Temple University, to investigate how silencing…
A white paper documenting presentations and discussions from the Mesothelioma Patient Registry workshop, which was convened by the Mesothelioma Applied Research Foundation in March of…
Last week, the 9th U.S. Circuit Court of Appeals delivered a ruling addressing certain issues with the Environmental Protection Agency’s (EPA) approach to assessing risk…
Editor’s Note: Cindy Wiese passed away Friday, June 12, 2020 at home. BY CINDY WIESE My mesothelioma journey started in April 2010 when I was…
Sandy Robb was a dedicated member of the Meso Foundation’s board of directors. He took his position seriously, never missing any meetings, and never shying…
Mavis Nye, a mesothelioma warrior and advocate from the United Kingdom, and her husband, Ray, will receive honorary degrees from the University of Kent in…
The Mesothelioma Applied Research Foundation (Meso Foundation) is pleased to announce that R. Taylor Ripley, MD and Jason M. Foster, MD have joined the organization’s…
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
